March 14th 2024
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
November 21st 2022
Bariatric Surgery Reduced Risk of Major Adverse Liver, CV Outcomes in Patients With NASH
November 18th 2021Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.
Read More
High Iron Levels in Blood Linked to Increased Risk of Liver Cancer in NAFLD
November 12th 2021Researchers conducted the study because although prior research has illustrated that elevated levels of iron in the blood from hereditary hemochromatosis can raise the risk of liver cancer, little is known about the effect of this condition in nonalcoholic fatty liver disease (NAFLD).
Read More
Children With HCC Have Higher Waitlist Mortality for Liver Transplant Than Children With HBL
November 5th 2021The higher waitlist mortality for liver transplant among children with hepatocellular carcinoma (HCC) compared with hepatoblastoma (HBL) indicates a need to improve prioritization for children with HCC.
Read More
Tremelimumab Added to Durvalumab Shows Positive Results in HCC
October 15th 2021There was statistically significant and clinically meaningful overall survival benefit vs sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) in top-line results from a phase 3 trial.
Read More
Prognostic Nutritional Index May Be Associated With Survival in HCC
September 24th 2021Researchers argue that Onodera’s prognostic nutritional index, calculated by lymphocytes and serum albumin to determine nutritional and immune status, is a straightforward method for use among patients undergoing liver surgery.
Read More
Children, Adolescents Considered Obese May Have Greater Risk of NAFLD
September 9th 2021This new study from investigators at Tel Aviv University looked at predictors of nonalcoholic fatty liver disease (NAFLD) among children and adolescents considered obese, because its predictors are not well known in this group.
Read More
Multidisciplinary Approach Important for Successful HCC Care
September 4th 2021Hepatocellular carcinoma (HCC) is challenging to diagnose and has an evolving treatment landscape, which makes a multidisciplinary approach to care important to ensure high-quality care and the best patient outcomes.
Read More
Fatty Liver Disease May Lower Risk of Cirrhosis, HCC in Patients With Comorbid Chronic Hepatitis B
August 5th 2021Patients with concurrent fatty liver disease and chronic hepatitis B exhibited higher cumulative rates of hepatitis B surface antigen seroclearance and lower cumulative rates of cirrhosis and hepatocellular carcinoma (HCC) across a 10-year period.
Read More